: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

King Beats, But Earnings Down

Thu, 05 Nov 2009 20:08:54 GMT

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

MFI Stock Review: Cephalon (CEPH)

Thu, 05 Nov 2009 16:56:11 GMT

Cephalon has three drugs with good growth potential. If sales develop according to the company's plan, the current price will prove to be a bargain.[More...]

EXACT Sciences (NASDAQ: EXAS): Patience Required For Long-Term Upside

Thu, 05 Nov 2009 01:21:28 GMT

On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company's progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1 million, operating expenses of $2.3 million, and ended the quarter with cash / equivalents of $26.9 million.[More...]

Celgene: Buy On A Pullback

Wed, 04 Nov 2009 17:04:19 GMT

“So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It’s approved by the FDA to treat multiple myeloma. That’s a cancer of the plasma cells and bone marrow. These cancers are horrible…[More...]

Jury convicts N.J. man of southside Lebanon bank robbery

Sat, 07 Nov 2009 07:45:00 GMT

Nov. 7--A federal jury has convicted a New Jersey man of robbing a southside Lebanon bank more than five years ago, the U.S. Attorney's office reported this week.
The verdict was returned after a three-day trial before U.S. District Court Chief Judge Yvette Kane.
The charges stem from the April 15, 2004, armed robbery of M&T Bank, 837 Quentin Road.

: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Bulls Back On Track?

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

King Beats, But Earnings Down

Your Kind of Day?

The Dollar-Proof Portfolio

MFI Stock Review: Cephalon (CEPH)

EXACT Sciences (NASDAQ: EXAS): Patience Required For Long-Term Upside

Celgene: Buy On A Pullback

Jury convicts N.J. man of southside Lebanon bank robbery

Carnegie Mellon exhibit blurs line between artist, tools

Strategist Offers Investing Tips

FDA: Byetta drug label is revised

State AGs suing U.S. drug maker Amgen

Business Highlights

Silicon Valley Stocks: Dow, Nasdaq, Symantec, LSI Climb

Silicon Valley Stocks: Tech Shares Slide; Nasdaq Falls 2.7 Percent

Biotech firm Cephalon 3Q profit falls 2.7 percent

Earnings roundup: Heartland Financial, Masco

Cytokinetics Announces Addition to Board of Directors

Achillion Reports Third Quarter Results

MethylGene Reports Third Quarter 2009 Financial Results

NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on WY, USO, NNN, WLT, TTI and AZO

42 Straight Profitable Trades Keep BullTrade.Com Subscribers Happy

United States Oil Fund Closed for 10.2% Gain By Galtstock Subscribers!

Dyadic International Reports Financial Results for First and Second Quarters of 2009 and Fiscal Years 2008 and 2007

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

Celgene Reports Record Third Quarter 2009 Operating and Financial Results

Form 4 RICHO ANNA For: Nov 05 (10K)

Form 4 BONANNI FABRIZIO For: Nov 05 (10K)

Form 4 Metza Kristen For: Nov 04 (10K)

Form 4 SHARER KEVIN W For: Nov 05 (10K)

Form 4 KLEIN JOSEPH III For: Nov 04 (10K)

Form 4 BOGER JOSHUA S For: Oct 27 (10K)

Form 4 Hamm Robert A For: Nov 04 (10K)

Form 4 GENZYME CORP For: Nov 03 Filed by: COONEY CHARLES L (10K)

Form 4 Alton Gregg H For: Nov 02 (10K)

Form 4 Hamm Robert A For: Nov 01 (10K)